Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Expert Review of Anticancer Therapy|November 30, 2016
Management of adverse events induced by next-generation immunomodulatory drug and proteasome inhibitors in multiple myelomaMarco Salvini, Francesca Bonello, Mario Boccadoro, et al.
Expert Opinion on Investigational Drugs|April 28, 2017
Novel investigational drugs active as single agents in multiple myelomaMattia D'Agostino, Marco Salvini, Antonio Palumbo, et al.
Leukemia & Lymphoma|October 8, 2015
Strategy for the treatment of multiple myeloma utilizing monoclonal antibodies: A new era beginsValeria Magarotto, Marco Salvini, Francesca Bonello, et al.
Expert Review of Anticancer Therapy|July 5, 2018
Determining treatment intensity in elderly patients with multiple myelomaMarco Salvini, Mattia D'Agostino, Francesca Bonello, et al.
Expert Opinion on Pharmacotherapy|June 30, 2017
Melphalan hydrochloride for the treatment of multiple myelomaFabrizio Esma, Marco Salvini, Rossella Troia, et al.
Expert Opinion on Drug Metabolism & Toxicology|December 14, 2017
Pharmacokinetic drug evaluation of ixazomib citrate for the treatment of multiple myelomaMarco Salvini, Rossella Troia, Davide Giudice, et al.
Cancers|May 7, 2019
Cardiovascular Organ Damage and Blood Pressure Levels Predict Adverse Events in Multiple Myeloma Patients Undergoing Carfilzomib TherapyGiulia Bruno, Sara Bringhen, Ilaria Maffei, et al.
Cancers|April 30, 2021
Multiple Myeloma Patients Undergoing Carfilzomib: Development and Validation of a Risk Score for Cardiovascular Adverse Events PredictionAnna Astarita, Giulia Mingrone, Lorenzo Airale, et al.
Frontiers in Cardiovascular Medicine|May 10, 2021
Effects of Carfilzomib Therapy on Left Ventricular Function in Multiple Myeloma PatientsGiulia Mingrone, Anna Astarita, Lorenzo Airale, et al.
Cancer|June 28, 2021
Carfilzomib, bendamustine, and dexamethasone in patients with advanced multiple myeloma: The EMN09 phase 1/2 study of the European Myeloma NetworkFrancesca Gay, Andreas Günther, Massimo Offidani, et al.
Pageof 2